Receptor-Targeted Full-Length IgG-Functionalized Lipid Nanoparticles: Types, Preparation, Characterization, and In Vivo Delivery

Receptor-Targeted Full-Length IgG-Functionalized Lipid Nanoparticles: Types, Preparation, Characterization, and In Vivo Delivery

What Are Receptor-Targeted Full-Length IgG-Functionalized Lipid Nanoparticles?

Receptor-targeted full-length immunoglobulin G (IgG)-functionalized lipid nanoparticles (IgG-LNPs) are engineered nanocarriers that display intact antibodies on their external surface to promote selective interactions with specific cell-surface receptors. A typical IgG molecule consists of two identical heavy chains and two identical light chains connected by disulfide bonds. Its structure contains two antigen-binding fragments (Fab), which recognize specific epitopes, and one crystallizable fragment (Fc), which interacts with Fc receptors and other components of the immune system. When attached to an LNP, the Fab regions are generally intended to remain accessible for receptor recognition, while the Fc region provides additional opportunities for orientation-controlled attachment or biological interactions.

The internal LNP structure generally contains an ionizable lipid, a helper phospholipid, cholesterol, and a PEG-lipid, with an encapsulated payload such as mRNA, siRNA, or plasmid DNA. Full-length IgG can be introduced through covalent attachment to functionalized PEG-lipids, Fc-directed capture systems, or other antibody-lipid conjugation approaches. Following administration, the antibody recognizes its corresponding cell-surface receptor and promotes particle association and, when the receptor supports internalization, cellular uptake. The lipid composition subsequently determines important intracellular processes, including endosomal escape and payload release.

Full-length IgG offers two antigen-binding sites and an intact Fc region, providing potential advantages in avidity, structural stability, and compatibility with Fc-directed surface attachment. However, its larger molecular size, bivalent binding, and Fc-mediated interactions can also introduce additional formulation and biological challenges. Antibody selection must therefore consider receptor expression, epitope accessibility, internalization behavior, Fc receptor interactions, and the intended delivery destination. Compared with smaller antibody-derived ligands, full-length IgG is not automatically the best choice for every LNP application. Fab fragments provide antigen recognition without an Fc region, single-chain variable fragments (scFv) offer a compact recombinant binding structure, and variable domains of heavy-chain-only antibodies (VHH) provide an even smaller single-domain alternative. The appropriate format depends on the required binding activity, surface density, steric accessibility, circulation behavior, and conjugation strategy.

Table 1. Comparison of Antibody Formats for Receptor-Targeted LNP Functionalization.

Antibody FormatStructural FeaturesAdvantages for LNP FunctionalizationKey Design Limitations
Full-Length IgGApproximately 150 kDa; two Fab regions and one Fc region; generally bivalent.Two antigen-binding sites, potentially strong multivalent interactions, and opportunities for Fc-directed orientation control.Large hydrodynamic size, possible Fc receptor interactions, steric crowding, and potential loss of binding activity after random conjugation.
FabApproximately 50 kDa; contains one antigen-binding site without an Fc region.Smaller surface footprint, accessible antigen-binding region, and reduced Fc-mediated interactions.Monovalent binding, potentially lower avidity, and additional fragment preparation requirements.
scFvApproximately 25-30 kDa; variable heavy and light domains connected by a flexible peptide linker.Compact structure, recombinant production flexibility, and potential for engineered attachment sites.Binding stability and aggregation behavior depend on sequence and linker design; no native Fc region.
VHHApproximately 12-15 kDa; a single variable domain derived from a heavy-chain-only antibody.Small size, potentially high surface density, good access to sterically restricted epitopes, and convenient site-specific modification.Single binding domain, no Fc-mediated interactions, and affinity and stability must be evaluated for each construct.

The full-length IgG format also presents an important structural trade-off. If an antibody is randomly attached through multiple lysine residues, some molecules may have their Fab regions oriented toward the LNP surface, reducing receptor accessibility. Conversely, attachment through an Fc-associated site can orient the antigen-binding regions outward. However, the resulting Fc presentation must also be considered because accessible Fc domains may interact with Fc gamma receptors on macrophages and other immune cells. Fc exposure can therefore influence both targeting specificity and nanoparticle clearance. Published research illustrates several approaches to this problem. A 2025 study introduced an Fc-binding single-domain antibody capture system, TP1107, to control the orientation of full-length mouse IgG1 on LNP surfaces. Optimally oriented anti-transferrin receptor antibodies showed improved cellular association and mRNA expression compared with randomly oriented antibodies. This provides a useful structural example of how antibody orientation can influence targeted LNP performance. The antibody capture approach and its experimental findings offer a reference for designing receptor-targeted full-length IgG-LNPs.

Table 2. Receptor-IgG-LNP Design Matrix for Different Research Applications.

Target ReceptorRepresentative Target CellsPotential Research ApplicationsKey IgG-LNP Design Considerations
CD4CD4+ helper T cells and selected CD4-expressing immune cell populations.Selective mRNA delivery, T-cell engineering, and gene modulation.Antibody epitope, receptor internalization, CD4 signaling effects, and non-target immune-cell association.
CD8CD8+ cytotoxic T cells and other CD8-expressing immune cell populations.Selective RNA delivery, T-cell engineering, and functional payload expression.CD8 alpha or beta recognition, antibody density, receptor engagement, and cell-subset specificity.
c-Kit (CD117)Hematopoietic stem cells and hematopoietic progenitor cells.In vivo RNA delivery, gene editing, and stem-cell population modification.CD117 expression distribution, receptor availability, antibody internalization, and bone marrow exposure.
EGFREGFR-expressing epithelial cells and placental trophoblast populations.Extrahepatic mRNA delivery and receptor-directed tissue targeting.Receptor expression, antibody epitope, internalization behavior, and surface antibody density.
HER2 (ERBB2)HER2-high cells and selected HER2-expressing tissue populations.Cell-selective mRNA delivery, reporter expression, and targeted payload evaluation.HER2 abundance, antibody orientation, bivalent receptor binding, and the distinction between local and systemic delivery.
Transferrin Receptor 1 (TfR1/CD71)Brain microvascular endothelial cells, erythroid progenitors, and other TfR1-expressing cells.Receptor-mediated cellular uptake and research into brain-directed delivery systems.Binding affinity, receptor valency, endothelial retention, transcytosis, and potential lysosomal routing.

BOC Sciences provides antibody-conjugated lipid nanoparticle development, including antibody and lipid building-block selection, conjugation chemistry, surface functionalization, LNP formulation, purification, and biological evaluation. The development strategy can be adjusted according to the target receptor, antibody format, payload properties, and intended administration route.

CD4-Targeted Full-Length IgG-Functionalized Lipid Nanoparticles

What Are CD4-Targeted IgG-Functionalized LNPs and When Is CD4 Targeting Needed?

CD4-targeted IgG-functionalized LNPs are lipid nanoparticles displaying full-length anti-CD4 antibodies on their external surface to promote recognition and uptake by CD4-expressing cells. CD4 is a transmembrane glycoprotein that functions as a co-receptor during T-cell receptor signaling. It is primarily associated with helper T cells but is also expressed by certain monocyte, macrophage, and dendritic cell populations. This expression pattern makes CD4 an attractive target for research requiring preferential delivery to CD4-expressing immune cells. The main reason to develop CD4-targeted LNPs is that conventional LNPs generally show limited productive delivery to resting T cells. Antibody binding can promote particle association with CD4 and stimulate receptor-associated internalization, creating an alternative entry pathway for encapsulated RNA. Depending on the antibody clone and epitope, CD4 engagement may also influence receptor signaling or cell behavior. Therefore, receptor recognition, internalization, and preservation of the intended cellular phenotype should be evaluated together.

A representative example was reported in a 2021 study entitled Highly Efficient CD4+ T Cell Targeting and Genetic Recombination Using Engineered CD4+ Cell-Homing mRNA-LNPs. The researchers conjugated full-length anti-CD4 monoclonal antibodies to mRNA-loaded LNPs and demonstrated selective delivery to CD4+ T cells. Following intravenous administration in mice, the targeted particles supported reporter expression and Cre-mediated genetic recombination in CD4+ cells in the spleen and lymph nodes. This study provides direct research evidence for full-length anti-CD4 antibody functionalization. The 2021 anti-CD4 mRNA-LNP study provides a useful reference for receptor selection and functional delivery evaluation. CD4 targeting is particularly relevant when the intended payload is designed to modify gene expression, introduce a transient protein, or evaluate intracellular RNA delivery in CD4+ immune populations. However, the target cell population must be defined before antibody selection. An antibody that recognizes CD4 across several immune cell types may produce a different distribution pattern from one selected for a particular T-cell subset.

Preparation of CD4-Targeted IgG-Functionalized LNPs

Preparation generally involves producing a payload-containing LNP core, introducing reactive groups onto its surface, modifying the full-length anti-CD4 IgG, and coupling the two components under controlled conditions. A common approach uses a maleimide-functionalized PEG-lipid as the surface attachment site and thiol-modified IgG as the targeting ligand.

Step 1: Base LNP preparation. The ionizable lipid, helper phospholipid, cholesterol, and PEG-lipid are combined with the selected RNA payload. Microfluidic mixing or another controlled assembly method can be used to establish particle size, polydispersity, encapsulation efficiency, and payload integrity. The base formulation should be characterized before antibody modification so that subsequent changes can be attributed to the conjugation process. BOC Sciences supports lipid nanoparticle synthesis and formulation development for different payload requirements.

Step 2: Surface maleimide introduction. A maleimide-bearing PEG-lipid, such as DSPE-PEG-maleimide, can be introduced into preformed LNPs through a post-insertion process. This provides accessible maleimide groups for subsequent antibody attachment. The PEG-lipid fraction and insertion conditions should be controlled because excessive surface modification may change particle size, colloidal stability, or receptor accessibility.

Step 3: Anti-CD4 IgG thiolation. SATA chemistry can introduce protected sulfhydryl groups onto accessible amino groups of the antibody. Following deprotection under controlled conditions, the resulting thiol-functionalized IgG can react with maleimide groups on the LNP surface to form stable thioether linkages. The degree of antibody modification should be limited to preserve antigen recognition and minimize intermolecular crosslinking.

Step 4: Antibody coupling. The thiolated anti-CD4 IgG is mixed with maleimide-functionalized LNPs under compatible buffer and temperature conditions. Antibody-to-particle feed ratio, reaction time, pH, and total antibody concentration should be optimized systematically. The objective is to obtain sufficient antibody surface density without promoting aggregation or excessive receptor crosslinking.

Alternative approaches include azide-DBCO strain-promoted cycloaddition and Fc-directed antibody capture. These methods can be considered when improved attachment selectivity or Fab accessibility is required. Nanoparticle conjugation services and nanoparticle surface functionalization services can support the evaluation of different attachment strategies.

Purification and Characterization of CD4-Targeted IgG-Functionalized LNPs

After conjugation, free antibodies, unreacted linker components, and soluble reaction byproducts must be removed. Size-exclusion chromatography is useful because LNPs and free IgG have different hydrodynamic sizes. Ultrafiltration can also be evaluated for particle concentration and buffer exchange, although membrane selection must account for particle recovery and the possible retention of soluble antibody aggregates.

Characterization should establish whether the antibody is attached to the particles, whether its antigen-binding function remains intact, and whether the original LNP structure has been preserved:

These measurements can be combined within a lipid nanoparticle characterization workflow. Additional particle size analysis, zeta potential analysis, and morphology characterization help determine whether antibody coupling has changed the physicochemical properties of the LNP.

In Vivo Delivery Strategies for CD4-Targeted IgG-Functionalized LNPs

Intravenous administration is a relevant starting route for CD4-targeted LNPs because it provides systemic access to circulating immune cells and lymphoid tissues. Following administration, antibody-functionalized particles can interact with CD4-expressing cells in the blood, spleen, and lymph nodes. However, the extent of delivery depends on antibody density, receptor accessibility, circulation behavior, and the ability of the LNP core to support intracellular payload release.

Several formulation variables require coordinated optimization:

The formulation should be compared with non-targeted LNPs and isotype IgG-functionalized controls. This helps determine whether the observed distribution is attributable to CD4 recognition rather than nonspecific interactions with immune cells or changes in the LNP surface.

Verifying Successful In Vivo Delivery of CD4-Targeted IgG-Functionalized LNPs

Successful delivery should be established at three separate levels: nanoparticle distribution, CD4+ cell uptake, and functional payload activity. Detecting an LNP-associated fluorescent or radioactive signal in the spleen does not independently prove that the encapsulated RNA has reached the cytosol or produced its intended biological effect.

A strong verification strategy should also assess whether CD4 targeting changes the distribution of the payload among different immune cell populations. Nanoparticle cellular uptake testing can support the evaluation of receptor-associated uptake, while functional RNA measurements establish whether increased cellular association leads to productive delivery.

Table 3. Development and Evaluation Workflow for CD4-Targeted IgG-LNPs.

Development StageRepresentative Methods and Readouts
Preparation and ConjugationMicrofluidic LNP preparation; DSPE-PEG-maleimide post-insertion; SATA-mediated IgG thiolation; thiol-maleimide coupling; size-exclusion purification. Evaluate antibody density, conjugation efficiency, and payload retention.
In Vitro ValidationDLS, PDI, zeta potential, morphology, CD4 binding, flow cytometry, receptor internalization, and reporter expression. Assess antibody accessibility, cellular selectivity, and functional RNA delivery.
Delivery RoutePrimarily intravenous administration for systemic immune-cell targeting; local administration when an accessible tissue is the intended target.
In Vivo VerificationWhole-body imaging, organ distribution, tissue flow cytometry, confocal microscopy, and reporter or gene-modulation analysis. Assess CD4+ cell selectivity and functional payload delivery.
Developing CD4-Targeted IgG-Functionalized LNPs?

BOC Sciences supports full-length anti-CD4 IgG selection, antibody-lipid conjugation, LNP formulation, surface density optimization, purification, and receptor-mediated cellular delivery evaluation.

CD8-Targeted Full-Length IgG-Functionalized Lipid Nanoparticles

What Are CD8-Targeted IgG-Functionalized LNPs and When Is CD8 Targeting Needed?

CD8-targeted IgG-functionalized LNPs are antibody-decorated lipid nanoparticles designed to recognize CD8-expressing immune cells, particularly cytotoxic T lymphocytes. CD8 functions as a co-receptor that supports T-cell receptor recognition of peptide-MHC class I complexes. Its expression is commonly associated with CD8+ T cells, although CD8 alpha-containing receptor forms can also occur on selected natural killer cells and dendritic cell populations. CD8 targeting is relevant when the intended payload needs to be preferentially delivered to CD8+ T cells rather than broadly distributed among immune cell populations. Potential research applications include mRNA-mediated protein expression, transient expression of engineered receptors, and gene modulation in cytotoxic T-cell subsets. Compared with non-targeted LNPs, anti-CD8 IgG decoration provides an additional recognition mechanism that can promote particle binding and receptor-associated uptake.

An important research example was reported in a 2025 study entitled In Vivo CAR T Cell Generation to Treat Cancer and Autoimmune Disease. The researchers developed CD8-targeted LNPs using an anti-CD8 antibody and an optimized ionizable lipid formulation. The resulting particles delivered CAR-encoding mRNA to CD8+ T cells in experimental models, including humanized mice. The work demonstrated the feasibility of using full-length antibody-based targeting to direct an LNP payload toward a defined T-cell population. The 2025 CD8-targeted LNP research provides a representative reference for antibody selection, formulation design, and in vivo delivery assessment. CD8 targeting should not be treated as interchangeable with CD4 targeting. The expression pattern of CD8 alpha and CD8 beta, the selected antibody epitope, and the internalization behavior of the receptor complex can all affect the final cell distribution. An anti-CD8 antibody recognizing CD8 alpha may interact with a broader range of immune populations than a ligand designed to recognize a more restricted CD8 receptor configuration.

Preparation of CD8-Targeted IgG-Functionalized LNPs

CD8-targeted LNP preparation follows the same general workflow used for other antibody-functionalized LNPs, but the antibody clone and surface presentation should be selected according to the desired CD8+ cell population. The formulation should be optimized to maintain accessible antigen-binding sites while preserving the original lipid nanoparticle structure.

Step 1: Select the anti-CD8 IgG. The antibody should recognize an accessible extracellular epitope of the intended CD8 receptor. Cross-reactivity with other immune cell populations should be evaluated, particularly when CD8 alpha is used as the targeting antigen. Antibody binding should also be assessed for possible effects on receptor function and T-cell behavior.

Step 2: Prepare the payload-containing LNP. The ionizable lipid, helper phospholipid, cholesterol, and PEG-lipid are combined with the selected mRNA or other nucleic acid payload. The base formulation should be optimized for particle size, encapsulation, stability, and intracellular release before antibody functionalization.

Step 3: Introduce the antibody attachment site. Maleimide-functionalized PEG-lipid can be incorporated into the particle surface through post-insertion. Alternatively, azide-functionalized lipid components can be used for click-chemistry-based attachment. The selected method should provide sufficient reactive groups without compromising the PEG layer or the stability of the LNP.

Step 4: Couple the full-length IgG. Anti-CD8 IgG can be modified with SATA to introduce sulfhydryl groups, followed by thiol-maleimide conjugation to the LNP. The reaction conditions should be controlled to avoid excessive antibody modification, interparticle crosslinking, and loss of antigen-binding activity.

Step 5: Optimize surface presentation. The antibody-to-lipid ratio should be screened across a range of surface densities. Both particle-associated antibody and receptor-binding activity should be quantified because increasing the amount of attached IgG does not necessarily improve productive uptake. Targeted LNP development can support the coordinated evaluation of ligand density, lipid composition, and payload delivery performance.

Purification and Characterization of CD8-Targeted IgG-Functionalized LNPs

Purification should remove unbound anti-CD8 IgG and soluble conjugation reagents while retaining the antibody-functionalized particles. Size-exclusion chromatography is useful for separating free antibody from larger LNP conjugates. Ultrafiltration can be evaluated for buffer exchange and particle concentration, with attention to membrane recovery and possible aggregation during concentration.

The characterization strategy should include both physicochemical measurements and receptor-specific functional analysis.

A useful characterization approach is to compare the full-length anti-CD8 IgG-LNP with an isotype IgG-LNP and a non-targeted LNP containing the same payload. This comparison helps separate receptor-specific effects from nonspecific protein adsorption and changes caused by the antibody modification itself. Lipid nanoparticle stability evaluation can help identify aggregation, particle growth, or changes in colloidal behavior after functionalization.

In Vivo Delivery Strategies for CD8-Targeted IgG-Functionalized LNPs

Intravenous administration is a major strategy for evaluating systemic CD8-targeted LNP delivery. It provides access to circulating T cells and immune-cell-rich tissues, including the spleen and lymph nodes. The final biodistribution depends on the ionizable lipid, PEG-lipid composition, particle size, antibody density, and the interaction between the antibody Fc region and circulating immune components.

The formulation should be designed around the intended T-cell population rather than relying solely on total CD8 expression. In particular, the selected antibody should be evaluated for its recognition of CD8 alpha or CD8 beta and for possible interactions with CD8-expressing non-T-cell populations.

Local administration can also be considered for accessible target tissues, but systemic delivery and local delivery should be evaluated separately because they produce different exposure profiles. The selected route must be supported by tissue-level and cell-specific measurements rather than inferred from the antibody's receptor affinity.

Verifying Successful In Vivo Delivery of CD8-Targeted IgG-Functionalized LNPs

Verification should establish whether the targeted particles reach CD8+ T cells, whether the cells internalize the LNPs, and whether the encapsulated payload produces a measurable functional response. Whole-organ fluorescence alone cannot distinguish CD8+ T-cell delivery from particle accumulation in other cell populations.

For mRNA-loaded particles, an important endpoint is the proportion of target cells expressing the encoded protein rather than the percentage of cells merely associated with an LNP label. In addition, the duration of expression and the distribution of expression among different T-cell subsets can help determine whether the formulation provides the intended delivery profile.Nanoparticle in vivo imaging and tissue-based cellular analysis can be integrated to evaluate the relationship between systemic distribution and functional payload delivery.

Table 4. Development and Evaluation Workflow for CD8-Targeted IgG-LNPs.

Development StageRepresentative Methods and Readouts
Preparation and ConjugationMicrofluidic LNP formulation; maleimide-PEG-lipid post-insertion; SATA-mediated anti-CD8 IgG modification; thiol-maleimide coupling; size-exclusion purification. Evaluate antibody loading and CD8 recognition.
In Vitro ValidationDLS, PDI, zeta potential, antibody quantification, CD8 binding, flow cytometry, cellular internalization, and reporter expression. Compare CD8+ and CD8-negative populations.
Delivery RouteIntravenous administration for circulating and lymphoid T-cell targeting; localized administration when appropriate for the intended tissue.
In Vivo VerificationWhole-body imaging, blood and organ distribution, flow cytometry, microscopy, reporter expression, and payload-specific functional measurements. Assess CD8+ cell selectivity and off-target association.
Need CD8-Targeted LNP Formulation and Antibody Conjugation?

BOC Sciences provides support for anti-CD8 IgG material selection, lipid-linker design, antibody conjugation, formulation optimization, and cell-specific delivery evaluation.

c-Kit (CD117)-Targeted Full-Length IgG-LNPs

What Are CD117-Targeted LNPs, and When Are They Needed?

CD117-targeted LNPs are lipid nanoparticles functionalized with antibodies recognizing the stem cell factor receptor, also known as c-Kit or CD117. This transmembrane receptor tyrosine kinase is expressed on hematopoietic stem cells (HSCs) and hematopoietic progenitor cells (HSPCs), as well as selected other cell populations. Its expression in hematopoietic compartments makes CD117 a useful targeting marker for research involving RNA delivery and genetic modification of stem and progenitor cells. Conventional LNPs often show limited delivery to HSCs following systemic administration. An anti-CD117 IgG displayed on the particle surface can promote recognition of CD117-expressing cells and support receptor-associated internalization. The objective is not simply to increase particle accumulation in bone marrow but to deliver functional RNA into the intended stem or progenitor cell population.

A representative study published in 2023, In Vivo RNA Delivery to Hematopoietic Stem and Progenitor Cells via Targeted Lipid Nanoparticles, developed c-Kit antibody-targeted LNPs for systemic RNA delivery. The formulation delivered both siRNA and mRNA to HSCs in rodents following intravenous administration. The study also reported high levels of genetic modification in HSPCs following delivery of Cre recombinase mRNA, demonstrating the potential of receptor-targeted LNPs for functional RNA delivery to these cells. The 2023 CD117-targeted LNP study provides a direct reference for the development of this formulation category. CD117 targeting is relevant when the research objective involves modifying hematopoietic stem and progenitor cell populations, evaluating gene-editing payloads, or studying RNA delivery to bone marrow-associated cells. However, CD117 is not exclusive to HSCs. Its expression in other cell types must be considered when interpreting tissue distribution and cell-specific delivery.

Synthesis Methods of CD117-Targeted LNPs

The preparation of CD117-targeted LNPs generally begins with a nucleic acid-loaded lipid nanoparticle, followed by surface modification with an anti-CD117 IgG. The formulation must balance the stability of the lipid core with the accessibility of the antibody and the receptor-binding behavior required for HSPC uptake.

Step 1: Select the antibody and payload. The anti-CD117 antibody should recognize an extracellular region of c-Kit that remains accessible after particle attachment. The selected epitope should be evaluated for its influence on receptor binding and internalization. Payload selection depends on the research objective, with mRNA suitable for transient protein expression and siRNA suitable for sequence-specific gene silencing.

Step 2: Formulate the LNP core. The ionizable lipid, helper phospholipid, cholesterol, and PEG-lipid are combined with the selected RNA payload. Microfluidic mixing provides a controlled method for producing particles with reproducible size and payload encapsulation. The lipid composition should be screened for compatibility with the intended bone marrow delivery route and the intracellular release requirements of the RNA.

Step 3: Functionalize the LNP surface. Maleimide-functionalized PEG-lipid can be incorporated into the particle surface through post-insertion. Full-length anti-CD117 IgG can then be thiolated using SATA chemistry and coupled to the maleimide groups. An Fc-directed capture strategy or an azide-DBCO reaction can also be considered when improved antibody orientation is required.

Step 4: Optimize antibody loading. The amount of anti-CD117 IgG should be varied systematically. Excessive surface density may cause steric crowding or receptor crosslinking, whereas insufficient loading may result in weak cell association. Antibody density should therefore be evaluated together with receptor binding, cellular internalization, and functional RNA expression.

Step 5: Purify and recover the conjugate. Size-exclusion chromatography or ultrafiltration can be evaluated to remove unbound IgG and soluble reaction components. The purification process should preserve the particle population and minimize RNA loss. Microfluidic LNP production services can support the preparation and process optimization of the underlying lipid nanoparticle system.

Purification and Characterization of CD117-Targeted LNPs

The purification objective is to obtain an LNP population with measurable particle-associated anti-CD117 IgG and minimal free antibody contamination. Because unbound antibody can interact with CD117 independently of the nanoparticle, residual free IgG may distort cellular uptake measurements. Separation efficiency should therefore be established through analysis of both the particle and soluble fractions.

Particular attention should be paid to the distinction between particle-associated antibody and antibody that is simply retained in the purified fraction. Free or weakly associated IgG can produce misleading receptor-binding results. A combination of protein quantification, separation analysis, and functional receptor-binding experiments provides stronger evidence of successful conjugation. Nanoparticle drug loading analysis can also support the evaluation of payload retention and loading characteristics after surface modification.

In Vivo Delivery Strategies for CD117-Targeted LNPs

Intravenous administration is an important route for CD117-targeted LNPs because circulating particles can access the bone marrow and interact with hematopoietic cell populations. Following administration, the anti-CD117 antibody promotes recognition of c-Kit-expressing cells, while the lipid core supports intracellular RNA delivery.

A key formulation challenge is that bone marrow accumulation does not necessarily indicate selective HSC or HSPC delivery. The bone marrow contains multiple cell populations, including stromal cells, endothelial cells, mature blood cells, and progenitor populations. Therefore, the antibody and lipid composition should be optimized for the intended cell subset rather than total tissue uptake.

Different payloads require different functional endpoints. Reporter mRNA can provide an initial indication of protein expression, while siRNA and gene-editing components require sequence-specific or editing-related measurements. The final formulation should be assessed using cell-specific analysis rather than relying solely on total bone marrow fluorescence.

Verification of In Vivo Delivery of CD117-Targeted LNPs

Verification should determine whether CD117-targeted particles reach the bone marrow, associate with the intended HSPC populations, and deliver their RNA payload in a functionally productive manner. This requires combining tissue distribution measurements with cell population analysis and payload-specific readouts.

It is important to distinguish the delivery of RNA to HSPCs from the modification of all bone marrow cells. A formulation may show strong organ-level accumulation while achieving only limited functional delivery to the intended stem-cell population. Combining tissue analysis, flow cytometry, and functional payload measurements provides a more complete assessment. Nanoparticle cellular and in vivo evaluation can support the integration of these different readouts.

Table 5. Development and Evaluation Workflow for CD117-Targeted LNPs.

Development StageRepresentative Methods and Readouts
Synthesis and ConjugationMicrofluidic RNA-LNP formulation; PEG-lipid surface functionalization; anti-CD117 IgG thiolation; maleimide coupling or Fc-directed attachment; size-exclusion purification. Evaluate antibody loading and payload retention.
In Vitro ValidationDLS, PDI, zeta potential, morphology, CD117 binding, HSPC uptake, flow cytometry, and reporter expression. Evaluate receptor-dependent internalization and functional RNA delivery.
Delivery RouteIntravenous administration for systemic access to bone marrow and circulating hematopoietic cell populations.
In Vivo VerificationBone marrow and spleen distribution, flow cytometry of HSC/HSPC subsets, tissue microscopy, receptor-blocking controls, and RNA expression or gene-modulation analysis.
Developing CD117-Targeted LNPs for HSPC Delivery?

BOC Sciences supports anti-CD117 antibody selection, lipid-linker conjugation, RNA encapsulation, LNP formulation, physicochemical characterization, and HSPC-targeted delivery evaluation.

Epidermal Growth Factor Receptor (EGFR)-Targeted Full-Length IgG-LNPs

What Are EGFR-Targeted LNPs, and When Are They Needed?

EGFR-targeted IgG-LNPs are lipid nanoparticles functionalized with full-length antibodies that recognize the extracellular domain of the epidermal growth factor receptor. EGFR is a transmembrane receptor tyrosine kinase involved in cell growth, proliferation, and intracellular signaling. Its expression varies among tissues and cell populations, making it a useful target for research involving receptor-directed nanoparticle uptake. EGFR targeting is particularly relevant when the intended cell population has accessible EGFR expression and conventional LNPs provide insufficient cellular selectivity. Antibody binding can promote particle retention at the cell surface and stimulate receptor-associated endocytosis. However, receptor expression alone does not guarantee efficient payload delivery. The antibody clone, epitope, receptor internalization rate, and intracellular trafficking pathway must also be considered.

A representative example was reported in a 2024 study entitled EGFR-Targeted Ionizable Lipid Nanoparticles Enhance In Vivo mRNA Delivery to the Placenta. The researchers introduced azide-functionalized PEG-lipids into LNPs and coupled DBCO-modified anti-EGFR antibodies through strain-promoted azide-alkyne cycloaddition. Their optimized intermediate antibody-density formulation produced approximately twofold higher mRNA delivery in mouse placentas and approximately twofold higher particle uptake in EGFR-expressing trophoblasts compared with non-targeted LNPs. The 2024 EGFR-targeted LNP study demonstrates the importance of antibody density and receptor-associated cellular uptake in extrahepatic delivery research.

EGFR-targeted LNPs may be considered for receptor-expressing epithelial cells, selected tissue populations, and other research models in which EGFR-mediated uptake is desirable. The intended application should be defined before formulation because EGFR expression and receptor turnover can differ substantially between tissues.

Synthesis Methods of EGFR-Targeted LNPs

EGFR-targeted LNPs can be prepared by introducing azide groups onto the LNP surface and subsequently coupling them with DBCO-functionalized full-length anti-EGFR IgG. This approach is attractive because the click reaction can proceed under relatively mild aqueous conditions without requiring the formation of a conventional amide bond directly between the antibody and lipid.

Step 1: Prepare the base formulation. The selected ionizable lipid, helper phospholipid, cholesterol, and PEG-lipid are combined with the payload. The formulation should first be optimized for particle size, PDI, encapsulation efficiency, and colloidal stability. The lipid composition should also support intracellular payload release after receptor-mediated uptake.

Step 2: Introduce azide-functionalized PEG-lipid. A portion of the PEG-lipid can be replaced with an azide-bearing PEG-lipid during particle assembly. This provides accessible reactive groups for subsequent antibody attachment. The amount of azide-functionalized lipid should be screened because excessive reactive-group density can increase surface modification and affect the colloidal properties of the particles.

Step 3: Modify the anti-EGFR IgG. The full-length antibody is functionalized with a DBCO-containing linker through an appropriate protein modification approach. The modification conditions should preserve the antibody's structural integrity and EGFR-binding activity. Random modification of lysine residues may be convenient, but it can produce heterogeneous conjugates and should be assessed for its effect on antigen accessibility.

Step 4: Perform click conjugation. The DBCO-modified anti-EGFR IgG is incubated with azide-functionalized LNPs. The reaction forms a stable triazole linkage between the antibody-associated DBCO group and the surface azide. Antibody feed ratio, reaction time, temperature, and buffer composition should be optimized to achieve the desired surface density.

Step 5: Purify and optimize. Unbound antibody and soluble reaction components are removed through size-exclusion chromatography or another suitable separation method. Different antibody densities should then be compared for receptor binding, particle size, payload retention, and functional expression. The objective is to identify a surface density that improves targeting without compromising the LNP core.

Purification and Characterization of EGFR-Targeted LNPs

Purification is necessary to remove free anti-EGFR IgG and residual coupling components. Size-exclusion chromatography is particularly useful for separating the larger nanoparticle fraction from free antibody. Ultrafiltration can be used for concentration and buffer exchange when the membrane retains the LNPs while allowing soluble impurities to pass through.

Following purification, the characterization workflow should include:

One important consideration is that the highest antibody loading does not necessarily provide the highest delivery efficiency. The 2024 EGFR-LNP study demonstrated that an intermediate antibody density performed better than simply maximizing surface functionalization. This supports a systematic screening approach that considers antibody accessibility, PEG shielding, and particle integrity together.

In Vivo Delivery Strategies for EGFR-Targeted LNPs

Intravenous administration can be considered when the target EGFR-expressing tissue is accessible through systemic circulation. In this setting, the anti-EGFR IgG promotes receptor recognition after the LNP reaches the target tissue. However, systemic delivery is influenced by blood exposure, protein adsorption, particle clearance, and receptor expression in non-target tissues.

Local administration may also be evaluated for accessible EGFR-expressing tissues when a high local particle concentration is desired. The route should be selected according to tissue accessibility, receptor distribution, payload properties, and the required distribution pattern.

The intended target tissue should be evaluated for EGFR abundance before administration. Where EGFR is expressed in multiple cell populations, the antibody's specificity and internalization behavior should be assessed in the relevant tissue context rather than inferred from receptor expression alone.

Verification of In Vivo Delivery of EGFR-Targeted LNPs

Verification should establish whether EGFR-targeted LNPs accumulate in the intended tissue, interact with EGFR-expressing cells, and deliver their payload productively. Particle distribution and mRNA expression should be measured separately because an increase in particle-associated fluorescence does not necessarily indicate increased protein expression.

For tissue-specific delivery, the analysis should distinguish particle accumulation in the organ from uptake by the intended cell type. For example, increased placental signal should be accompanied by cellular analysis to determine whether the particles are associated with trophoblasts, endothelial cells, or immune populations. Nanoparticle in vivo distribution analysis can support quantitative organ-level assessment and help interpret the results alongside cell-specific functional measurements.

Table 6. Development and Evaluation Workflow for EGFR-Targeted LNPs.

Development StageRepresentative Methods and Readouts
Synthesis and ConjugationIonizable LNP formulation; azide-functionalized PEG-lipid incorporation; DBCO-modified anti-EGFR IgG; strain-promoted azide-alkyne cycloaddition; size-exclusion purification. Evaluate antibody density and coupling efficiency.
In Vitro ValidationDLS, PDI, zeta potential, cryo-TEM, EGFR binding, flow cytometry, receptor internalization, and reporter expression. Evaluate receptor-dependent uptake and payload activity.
Delivery RouteIntravenous administration for systemic tissue targeting or localized administration for accessible EGFR-expressing tissues.
In Vivo VerificationWhole-body imaging, organ distribution, tissue microscopy, cell-specific flow cytometry, receptor-blocking controls, and reporter or gene-modulation analysis.
Developing EGFR-Targeted LNPs for Extrahepatic Delivery?

BOC Sciences provides anti-EGFR IgG conjugation, azide-DBCO linker selection, antibody density optimization, LNP formulation, and receptor-dependent delivery evaluation.

HER2-Targeted Full-Length IgG-Functionalized Lipid Nanoparticles

What Are HER2-Targeted IgG-Functionalized LNPs and When Is HER2 Targeting Needed?

HER2-targeted IgG-functionalized LNPs are lipid nanoparticles decorated with full-length antibodies that recognize human epidermal growth factor receptor 2 (HER2), also known as ERBB2. HER2 is a member of the epidermal growth factor receptor family and functions as a transmembrane receptor tyrosine kinase. Its expression varies among cell populations, and elevated receptor abundance can provide an opportunity for selective nanoparticle recognition. Full-length anti-HER2 IgG can provide two antigen-binding sites for receptor recognition and may improve particle association through multivalent interactions. Trastuzumab is a representative anti-HER2 IgG that has been investigated as a targeting ligand for LNP surface functionalization. Its antigen-binding regions recognize HER2, while its Fc region can be used as an attachment interface in Fc-directed conjugation systems.

A relevant study published on November 1, 2026, entitled FcBP-HFQ Lipid-Mediated Trastuzumab Modification of mRNA-Loaded Lipid Nanoparticles Enhances Delivery to HER2-Expressing Cancer Cells, demonstrated an orientation-controlled approach for attaching trastuzumab to mRNA-loaded LNPs. The modified particles showed more than 100-fold greater cellular association than unmodified LNPs in HER2-overexpressing cells. In a mouse model, intratumoral administration of trastuzumab-modified LNPs also produced higher luciferase expression than the corresponding non-targeted and isotype-controlled formulations. The 2026 trastuzumab-functionalized LNP study provides a recent example of Fc-directed antibody orientation and HER2-selective payload delivery.

HER2 targeting is relevant when the objective is to increase LNP association with HER2-expressing cells and evaluate selective mRNA delivery. However, the published intratumoral delivery result should not be interpreted as proof of improved systemic tumor targeting. Local administration, systemic distribution, and functional delivery are distinct experimental questions that require separate evaluation.

Preparation of HER2-Targeted IgG-Functionalized LNPs

HER2-targeted LNPs can be prepared using several antibody attachment approaches. These include conventional thiol-maleimide conjugation, azide-DBCO click chemistry, and Fc-directed attachment systems. For full-length trastuzumab or another anti-HER2 IgG, the selected approach should preserve Fab accessibility and minimize unwanted interactions involving the Fc region.

Step 1: Select the anti-HER2 antibody. The antibody should recognize an accessible HER2 epitope and retain sufficient binding activity after surface attachment. Its binding affinity, valency, species reactivity, and potential to promote receptor clustering should be considered during selection.

Step 2: Formulate the payload-containing LNP. The ionizable lipid, helper phospholipid, cholesterol, and PEG-lipid are combined with the selected mRNA or other payload. The core formulation should be optimized before antibody attachment to establish baseline particle size, encapsulation, and functional expression.

Step 3: Introduce the antibody attachment architecture. A maleimide-functionalized PEG-lipid can be introduced into the LNP through post-insertion. Alternatively, an Fc-binding lipid or an Fc-directed capture component can be used to position the antibody with its Fab regions facing the surrounding aqueous environment. The latter approach is particularly relevant when random attachment produces heterogeneous antibody orientations.

Step 4: Attach the full-length anti-HER2 IgG. Depending on the selected architecture, the antibody can be modified with thiol-reactive groups or captured through an Fc-recognition component. Reaction conditions should be optimized to avoid antibody aggregation, loss of receptor recognition, and changes in particle size.

Step 5: Screen antibody surface density. Multiple antibody-to-lipid ratios should be compared. The optimal density is determined by the relationship between HER2 binding, cellular internalization, particle stability, and functional payload expression rather than by the amount of attached antibody alone.

For projects requiring a specialized antibody-lipid structure, BOC Sciences can support custom synthesis of selected linker and functionalized lipid building blocks according to the intended conjugation architecture.

Purification and Characterization of HER2-Targeted IgG-Functionalized LNPs

Purification should remove free anti-HER2 IgG, unreacted lipid-linker components, and soluble reaction byproducts. Size-exclusion chromatography is a suitable option when the particle and antibody fractions can be separated according to hydrodynamic size. Ultrafiltration can also be considered for concentration and buffer exchange.

Characterization should establish the quality of the antibody-LNP interface and confirm that the underlying particle remains suitable for payload delivery.

A particularly important measurement is the ratio between particle association and functional payload expression. High HER2 binding does not necessarily produce high cytosolic delivery. If particles bind efficiently but show limited reporter expression, intracellular trafficking and endosomal escape should be investigated separately.

In Vivo Delivery Strategies for HER2-Targeted IgG-Functionalized LNPs

Intratumoral administration is a useful starting strategy when the research objective is to evaluate local delivery to an accessible HER2-expressing tissue. It provides direct particle exposure at the target site and can help establish whether antibody functionalization improves cell association and payload expression. However, local injection does not independently establish the ability of the formulation to reach distant target tissues after systemic administration.

Intravenous delivery may be evaluated when systemic access to HER2-expressing tissues is required. In this case, the formulation must be optimized for circulation behavior, tissue penetration, and cell-specific receptor recognition. Particle size, antibody density, PEG content, and the degree of protein adsorption can all influence the resulting distribution.

The administration route should be selected according to the specific research objective. Local tissue expression, systemic organ distribution, and selective uptake by HER2-expressing cells should be treated as separate endpoints.

Verifying Successful In Vivo Delivery of HER2-Targeted IgG-Functionalized LNPs

Verification should determine whether the particles reach the HER2-expressing tissue, whether they associate with the intended cell population, and whether the encapsulated payload is functionally delivered. Both tissue-level and cellular-level analysis are required to avoid interpreting nonspecific particle retention as receptor-specific delivery.

For intratumoral studies, samples should be collected from different regions of the target tissue to determine whether payload expression is spatially distributed or concentrated near the injection site. For systemic studies, target-to-off-target tissue ratios and cell-specific expression are more informative than total organ fluorescence alone.

A useful assessment combines nanoparticle in vitro evaluation with tissue distribution, cellular uptake, and functional payload measurements to establish the relationship between receptor recognition and productive delivery.

Table 7. Development and Evaluation Workflow for HER2-Targeted IgG-LNPs.

Development StageRepresentative Methods and Readouts
Preparation and ConjugationIonizable LNP preparation; maleimide-PEG-lipid incorporation, Fc-directed capture, or other controlled conjugation chemistry; anti-HER2 IgG attachment; antibody density screening; size-exclusion purification.
In Vitro ValidationDLS, PDI, zeta potential, morphology, HER2 binding, antibody orientation assessment, flow cytometry, intracellular localization, and reporter expression in HER2-high and HER2-low cells.
Delivery RouteIntratumoral administration for local tissue delivery studies; intravenous administration for systemic distribution and target-cell delivery evaluation.
In Vivo VerificationWhole-body imaging, tissue distribution, cell-specific uptake, receptor-blocking controls, spatial microscopy, and functional reporter expression.
Developing HER2-Targeted IgG-Functionalized LNPs?

BOC Sciences supports full-length anti-HER2 IgG selection, Fc-directed conjugation, functionalized lipid synthesis, LNP formulation, antibody orientation optimization, and targeted payload delivery evaluation.

Transferrin Receptor (TfR1)-Targeted Full-Length IgG-Functionalized Lipid Nanoparticles

What Are TfR1-Targeted IgG-Functionalized LNPs and When Is TfR1 Targeting Needed?

TfR1-targeted IgG-functionalized LNPs are lipid nanoparticles displaying full-length antibodies that recognize transferrin receptor 1, also known as CD71. TfR1 is a transmembrane glycoprotein involved in cellular iron uptake through transferrin binding and receptor-mediated endocytosis. It is expressed in several cell populations, including brain microvascular endothelial cells and erythroid progenitor cells, making it an important target for receptor-mediated delivery research. TfR1 is of particular interest in brain-directed delivery research because it is present on the luminal surface of brain microvascular endothelial cells. Antibody recognition of TfR1 can promote endothelial binding and internalization, creating an opportunity to investigate receptor-associated transport across the blood-brain barrier (BBB). However, endothelial uptake and successful transport into brain parenchyma are different biological events. Full-length IgG-LNPs may remain associated with the vascular endothelium or undergo intracellular degradation rather than completing transcytosis.

A representative antibody-functionalization approach was described in a 2025 study entitled A Versatile Antibody Capture System Drives Specific In Vivo Delivery of mRNA-Loaded Lipid Nanoparticles. The researchers developed an Fc-binding single-domain antibody capture system that enabled full-length anti-TfR IgG to be displayed on LNPs with controlled orientation. Optimally oriented antibodies showed improved cell binding and mRNA expression compared with randomly oriented antibodies, demonstrating the importance of maintaining accessible Fab regions. The 2025 antibody-capture LNP study provides a useful reference for full-length IgG orientation and surface attachment.

TfR1-targeted LNPs may be considered for research involving brain endothelial cells, receptor-mediated internalization, and the development of brain-directed delivery systems. However, the cited full-length IgG-LNP research establishes an antibody orientation and receptor-binding approach, not definitive proof that these particles cross the BBB and deliver RNA into brain parenchymal cells. Such transport must be demonstrated independently.

Preparation of TfR1-Targeted IgG-Functionalized LNPs

Preparation of TfR1-targeted LNPs requires a strategy that preserves antibody recognition while controlling the geometry of receptor engagement. This is particularly important because TfR1 is a recycling receptor, and the affinity, valency, and binding position of the antibody can influence receptor trafficking.

Step 1: Select the anti-TfR1 IgG. Antibody selection should consider species specificity, receptor-binding affinity, epitope accessibility, and bivalent binding behavior. High affinity is not necessarily optimal for transport across the BBB. Strong receptor retention may increase endothelial association but may also limit the release of particles into downstream compartments.

Step 2: Prepare the LNP core. The base formulation can contain an ionizable lipid, helper phospholipid, cholesterol, and PEG-lipid, together with the selected RNA payload. Particle size, lipid composition, and PEG content should be optimized before antibody attachment. For brain-directed research, the core formulation must be assessed for systemic stability and compatibility with the intended transport mechanism.

Step 3: Introduce an Fc-directed capture component. An Fc-binding component can be anchored to the LNP surface through a functionalized lipid or PEG-lipid. The attachment site should be selected so that the Fc-binding interface is oriented toward the aqueous environment and can recognize the Fc region of the full-length IgG.

Step 4: Capture the full-length anti-TfR1 IgG. The antibody is incubated with the Fc-functionalized LNP under conditions that allow association through its Fc region. This can orient the two Fab regions outward and reduce the random attachment associated with conventional lysine-directed conjugation. Antibody loading and capture efficiency should be measured after the reaction.

Step 5: Evaluate receptor-binding geometry. Different antibody densities and capture configurations should be compared for TfR1 binding, cellular internalization, and payload expression. If conventional covalent coupling is used instead, the effect of random antibody orientation should be measured rather than assumed to be negligible.

PEG-lipid content and linker length should be adjusted together because the distance between the antibody and the particle surface can influence receptor accessibility. LNP PEG-lipid optimization can support the evaluation of surface shielding, ligand exposure, and particle stability.

Purification and Characterization of TfR1-Targeted IgG-Functionalized LNPs

Purification should remove unbound antibody and any soluble capture components while retaining the Fc-mediated antibody-LNP association. Size-exclusion chromatography is a suitable approach when free IgG and the particle-associated fraction can be adequately separated. Ultrafiltration may be used for concentration and buffer exchange, provided that the capture complex remains stable during processing.

Characterization should focus on particle integrity, antibody orientation, receptor recognition, and the stability of the capture interface.

For TfR1-targeted formulations, antibody affinity and binding valency should be considered alongside surface density. Excessive receptor avidity may produce strong endothelial association without productive transport. Therefore, binding measurements should be complemented by internalization and intracellular trafficking analysis.

In Vivo Delivery Strategies for TfR1-Targeted IgG-Functionalized LNPs

Intravenous administration is the primary route to investigate systemic TfR1-targeted delivery because it exposes the particles to the luminal surface of brain microvascular endothelial cells. After circulation, the antibody may recognize TfR1 and promote particle binding or receptor-associated internalization. Whether the particle is transported across the endothelial barrier depends on receptor trafficking, antibody affinity, particle size, and the structure of the LNP surface.

Several factors require particular attention:

A brain-directed research strategy should distinguish at least three outcomes: vascular endothelial association, movement beyond the endothelial layer, and functional payload expression in brain parenchymal cells. These endpoints require separate experimental measurements. BOC Sciences provides brain-targeted LNP development to support the evaluation of formulation and delivery strategies for this type of research.

Verifying Successful In Vivo Delivery of TfR1-Targeted IgG-Functionalized LNPs

Verification of TfR1-targeted LNP delivery requires more than demonstrating particle accumulation in the brain. Because TfR1 is highly expressed on brain endothelial cells, a substantial particle-associated signal may remain within the cerebral vasculature without reaching neurons, astrocytes, or other parenchymal cell populations.

A particularly important distinction is that increased brain-associated fluorescence does not necessarily indicate productive delivery to brain parenchymal cells. The lipid label, antibody, and RNA payload may exhibit different distribution patterns after administration. Where possible, particle-associated and payload-associated signals should be tracked independently.

Intracellular trafficking and endosomal release should also be assessed. If TfR1-targeted LNPs reach the intended cells but show limited protein expression, the limiting factor may be intracellular payload release rather than receptor recognition. LNP endosomal escape evaluation can help investigate this stage of the delivery process.

Table 8. Development and Evaluation Workflow for TfR1-Targeted IgG-LNPs.

Development StageRepresentative Methods and Readouts
Preparation and ConjugationIonizable LNP formulation; Fc-binding lipid or PEG-lipid introduction; full-length anti-TfR1 IgG capture; orientation and antibody-density screening; size-exclusion purification. Evaluate receptor binding and capture stability.
In Vitro ValidationDLS, PDI, zeta potential, morphology, antibody quantification, TfR1 binding, receptor internalization, intracellular trafficking, and reporter expression.
Delivery RouteIntravenous administration for systemic exposure to brain microvascular endothelium and other TfR1-expressing tissues.
In Vivo VerificationWhole-body imaging, brain and organ distribution, vascular perfusion, capillary depletion, cell-specific microscopy, receptor-blocking controls, and functional payload expression in brain tissue fractions.
Developing TfR1-Targeted IgG-LNPs for Brain Delivery Research?

BOC Sciences supports anti-TfR1 IgG selection, Fc-directed surface attachment, functionalized lipid synthesis, PEG-lipid optimization, LNP characterization, and brain-directed delivery evaluation.

BOC Sciences Support for Receptor-Targeted Full-Length IgG-LNP Development

IgG Selection, Engineering, and Linker Design

The selection of full-length IgG is a critical starting point for receptor-targeted LNP development. BOC Sciences can support project-specific material selection and design considerations based on the target receptor, intended cell population, payload, and administration route. Relevant parameters include antibody subclass, species reactivity, receptor-binding affinity, epitope accessibility, valency, and Fc-related interactions. Linker design should be coordinated with the antibody structure and intended surface attachment mechanism. Potential approaches include thiol-maleimide coupling, azide-DBCO click chemistry, Fc-directed capture, and other functionalized lipid architectures. The selected linker should provide sufficient spacing between the LNP surface and the antibody while maintaining colloidal stability and antigen accessibility. BOC Sciences can also support the selection and custom preparation of project-specific lipid-linker building blocks.

IgG-LNP Conjugation, Purification, and Process Development

BOC Sciences supports the development of full-length IgG-LNP conjugation strategies according to the requirements of different receptor-targeting projects. This includes the introduction of reactive lipid components, antibody modification, conjugation condition screening, and optimization of antibody-to-particle ratios. Purification development can focus on separating free antibody and soluble reaction components from the particle-associated fraction while maintaining nanoparticle recovery. Size-exclusion chromatography, ultrafiltration, and other suitable separation methods can be evaluated according to particle size, antibody characteristics, and formulation composition. Process optimization can also address particle aggregation, antibody loss, and payload leakage during purification.

Physicochemical and Functional Characterization

BOC Sciences can support integrated characterization of receptor-targeted IgG-LNPs to establish the relationship between antibody attachment, particle structure, and payload properties. Physicochemical measurements may include hydrodynamic diameter, PDI, zeta potential, morphology, antibody loading, encapsulation efficiency, and colloidal stability. Functional characterization can include receptor-binding activity, antibody accessibility, cellular association, receptor-mediated internalization, and payload expression or gene modulation. Comparing targeted LNPs with non-targeted and isotype antibody controls can help identify the contribution of the targeting ligand to the observed biological response.

Cellular and In Vivo Targeting Evaluation

BOC Sciences can support cellular evaluation of receptor-targeted IgG-LNPs using appropriate receptor-expressing cell populations and control models. These studies can investigate antibody-mediated binding, cellular uptake, intracellular localization, and functional payload delivery. Receptor expression and internalization behavior can be considered when comparing different antibody clones or targeting architectures. In vivo evaluation can be designed around the intended target tissue and administration route. Potential readouts include whole-body imaging, organ distribution, tissue-level particle accumulation, cell-specific uptake, and functional payload expression. For brain-directed formulations, additional evaluation can distinguish vascular association from delivery beyond the endothelial barrier. For immune-cell-targeted LNPs, flow cytometry can help establish the distribution of payload expression across specific immune cell populations.

Table 9. BOC Sciences Services for Receptor-Targeted Full-Length IgG-LNP Development.

Service NameDescriptionInquiry
Full-Length IgG-LNP Conjugation DevelopmentDevelopment of antibody-functionalized LNPs through thiol-maleimide coupling, click chemistry, Fc-directed capture, and other suitable surface attachment approaches.Inquiry
Custom IgG-Lipid Linker SynthesisCustom preparation of functionalized lipids, PEG-lipid linkers, and antibody attachment building blocks according to project-specific structural requirements.Inquiry
Receptor-Targeted LNP FormulationSelection of ionizable lipids, helper phospholipids, cholesterol, and PEG-lipids, with optimization of payload encapsulation and antibody surface density.Inquiry
IgG-LNP Purification and CharacterizationEvaluation of particle size, PDI, zeta potential, morphology, antibody incorporation, payload encapsulation, and colloidal stability after conjugation.Inquiry
Receptor-Mediated Cellular Uptake EvaluationAssessment of receptor binding, cellular association, internalization, cell-subset selectivity, and functional payload delivery using suitable target and control populations.Inquiry
Intracellular Localization and Endosomal Escape EvaluationInvestigation of intracellular particle trafficking, endosomal localization, payload release, and productive intracellular delivery.Inquiry
In Vivo Biodistribution and Functional Delivery EvaluationAssessment of whole-body distribution, organ accumulation, target-cell association, tissue localization, and functional payload expression after administration.Inquiry

Conclusion

Receptor-targeted full-length IgG-functionalized lipid nanoparticles provide a versatile approach for directing nucleic acid delivery toward selected cell populations. CD4- and CD8-targeted LNPs offer strategies for immune-cell delivery, CD117-targeted particles provide an approach for modifying hematopoietic stem and progenitor cells, EGFR- and HER2-targeted formulations support receptor-directed delivery to selected tissue and cell populations, and TfR1-targeted systems provide a research platform for investigating receptor-mediated uptake at the brain endothelium. Each receptor requires a distinct antibody selection strategy and a delivery workflow adapted to its expression pattern, internalization behavior, and biological environment. BOC Sciences provides support for full-length IgG material selection, antibody-lipid conjugation, custom linker synthesis, LNP formulation, purification, physicochemical characterization, receptor-mediated cellular uptake, and in vivo biodistribution evaluation. By integrating antibody engineering considerations with lipid formulation and biological assessment, BOC Sciences can help researchers develop receptor-targeted IgG-LNP platforms tailored to different payloads, target cells, and delivery objectives.

* Please kindly note that our services can only be used to support research purposes (Not for clinical use).
Online Inquiry
Verification code